NYSE$NVST
Envista Holdings Corporation · Q1 2025 earnings
Q1 2025 earnings · · After market close · Investor relations
Briefing
Envista reported Q1 2025 sales of $616.9M with net income of $18.0M and diluted EPS of $0.10.
Sales were $616.9 million, down slightly from $623.6 million, as dental consumables and equipment demand normalized post-pandemic. Net income was $18.0 million; diluted EPS was $0.10. Nobel Biocare and Kerr divisions face mixed regional trends.
- Q1 sales $616.9M (-1% YoY).
- Net income $18.0M; diluted EPS $0.10.
- Dental implant and consumables portfolio.
- Operating margin pressure from mix and FX.
- Spin-off from Danaher legacy cost structure.
Headline financials
Revenue & EPS history
Envista · Revenue · Quarterly
$617M
Revenue by segment
Envista · $631M total across 2 segments · Q3 2023
- Specialty Products & Technologies$400M+1.0%63.3%
- Equipment & Consumables$232M-1.7%36.7%
Forward guidance
Envista discusses market growth in implants and clear aligners, cost actions, and portfolio simplification; quarterly EPS guide on calls.
Tailwinds
- Aging population and dental procedure recovery.
- Nobel Biocare innovation pipeline.
- Cost reduction and footprint optimization.
Headwinds
- China and Europe dental market softness.
- Distributor inventory adjustments.
- Competitive pricing in consumables.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2025
-0.1%
Avg return
Earnings day
+1.6%
Avg return
5 days after
-0.8%
Avg return
30 days after
48%
16 / 33 earnings
Positive
+17.8%
Q4 2025
Best reaction
-9.7%
Q1 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.5% | -10.3% | -14.7% | |
| Q4 2025 | +17.8% | +22.5% | +8.7% | |
| Q3 2025 | -0.2% | +0.0% | +3.8% | |
| Q1 2025 | +3.8% | +3.1% | +11.8% | |
| Q4 2024 | +5.9% | +2.2% | -10.4% | |
| Q3 2024 | +11.6% | +13.3% | +18.6% | |
| Q2 2024 | +4.7% | +2.9% | +10.7% | |
| Q1 2024 | +0.7% | -3.2% | -1.6% | |
| Q4 2023 | -8.5% | -7.0% | -13.4% | |
| Q3 2023 | -8.7% | -8.3% | +2.7% | |
| Q2 2023 | +0.8% | +2.8% | -4.8% | |
| Q1 2023 | -6.4% | -7.1% | -12.0% | |
| Q4 2022 | -3.0% | -3.5% | -9.8% | |
| Q3 2022 | +2.8% | +3.4% | +4.0% | |
| Q2 2022 | +1.3% | +1.4% | -11.3% | |
| Q1 2022 | +7.5% | +5.4% | +6.2% | |
| Q4 2021 | +8.7% | +8.0% | +3.9% | |
| Q3 2021 | +5.4% | +6.1% | -3.9% | |
| Q2 2021 | -7.5% | -6.1% | +0.3% | |
| Q1 2021 | +2.1% | +3.1% | -4.1% | |
| Q4 2020 | +2.2% | +3.6% | +4.7% | |
| Q3 2020 | +7.8% | +9.9% | +20.4% | |
| Q2 2020 | -3.8% | +0.4% | +5.2% | |
| Q1 2019 | -9.7% | -8.9% | +10.7% | |
| Q1 2020 | -9.7% | -8.9% | +10.7% | |
| Q4 2019 | -6.5% | -8.1% | -19.8% | |
| Q4 2018 | -3.2% | +5.3% | -5.9% | |
| Q4 2017 | -3.2% | +5.3% | -5.9% | |
| Q3 2018 | -3.2% | +5.3% | -5.9% | |
| Q3 2019 | -3.2% | +5.3% | -5.9% | |
| Q2 2019 | -3.2% | +5.3% | -5.9% | |
| Q2 2018 | -3.2% | +5.3% | -5.9% | |
| Q1 2018 | -3.2% | +5.3% | -5.9% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro